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Introduction A principal aim of the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) was to
document changes in treatment practice for patients with newly diagnosed atrial fibrillation during an era when non–vitamin K
antagonist oral anticoagulants (NOACs) were becoming more widely adopted. In these analyses, the key factors which
determined the choice between NOACs and vitamin K antagonists (VKAs) are explored.
Methods Logistic least absolute shrinkage and selection operator regression determined predictors of NOAC and VKA
use. Data were collected from 24,137 patients who were initiated on AC ± antiplatelet (AP) therapy (NOAC [51.4%] or VKA
[48.6%]) between April 2013 and August 2016.
Results The most significant predictors of AC therapy were country, enrolment year, care setting at diagnosis, AF type,
concomitant AP, and kidney disease. Patients enrolled in emergency care or in the outpatient setting were more likely to receive
a NOAC than those enrolled in hospital (OR 1.16 [95% CI: 1.04-1.30], OR: 1.15 [95% CI: 1.05-1.25], respectively). NOAC
prescribing seemed to be favored in lower-risk groups, namely, patients with paroxysmal AF, normotensive patients, and those
with moderate alcohol consumption, but also the elderly and patients with acute coronary syndrome. By contrast, VKAs were
preferentially used in patients with permanent AF, moderate to severe kidney disease, heart failure, vascular disease, and
diabetes and with concomitant AP.
Conclusion GARFIELD-AF data highlight marked heterogeneity in stroke prevention strategies globally. Physicians are
adopting an individualized approach to stroke prevention where NOACs are favored in patients with a lower stroke risk but
also in the elderly and patients with acute coronary syndrome. (Am Heart J 2019;213:35-46.)
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Clinical Investigation
Atrial fibrillation (AF) is a strong independent risk
factor for ischemic stroke, which often manifests in
combination with other cardiovascular conditions, such
as hypertension, diabetes, coronary artery disease, or
heart failure, to further increase the thromboembolic
risk.1 AF-related stroke tends to be more severe and
debilitating, requiring longer hospitalization (than stroke
without AF), and so the costs of this arrhythmia to health
care systems and to society are enormous.2,3 Stroke
prevention with either vitamin K antagonists (VKAs),
usually warfarin, or non–vitamin K antagonist oral
anticoagulants (NOACs) is a principal component in the
management of AF patients with increased risk of
stroke.4-6 NOACs are at least as effective as VKAs for
embolic stroke prevention but are associated with less
bleeding (in particular, intracranial hemorrhage).5,7
NOACs are also easier for patients to use and for
physicians to manage because they can be given in
fixed doses without routine coagulation monitoring.8,9
However, VKAs (despite their recognized limitations
including interactions with foods and/or drugs, a narrow
therapeutic window, and difficulties in maintaining
adequate time in therapeutic range) have remained the
standard of care for stroke prevention in many settings
because of their low acquisition costs and established
monitoring services, which allow physicians to monitor
patient adherence.10-12
The Global Anticoagulant Registry in the FIELD-Atrial
Fibrillation (GARFIELD-AF; ClinicalTrials.gov Identifier:
NCT01090362) provided an opportunity to record
prospectively the choice of the anticoagulant (AC) first
prescribed in patients with newly diagnosed AF. Initial
analyses revealed an increase in the use of ACs from
57.4% to 71.2% of patients between 2010 and 2016.13,14
The aim of this analysis is to evaluate the factors (patient
characteristics, year of enrolment by cohort, care
settings, and geographic location) which have played a
role in determining the choice of the AC type during
these years of changing treatment practice.
Methods
Study design and participants
GARFIELD-AF is an ongoing prospective noninterven-
tional registry of patients with newly diagnosed AF which
is being conducted in 35 countries. The registry is
designed to reflect patient management according to
local practices, and all eligible patients were enrolled
prospectively and consecutively into the study without
exclusions according to comorbidities or treatment.
Investigator sites were mainly selected randomly from a
list of representative care settings in each participating
country.15 Treatment was neither mandated nor paid for
by a sponsor, and no additional visits, tests or procedures
were required to participate in the study. Adults
≥18 years were eligible for inclusion if they had
nonvalvular AF diagnosed according to standard local
procedures within 6 weeks of enrolment, had at least 1
risk factor for stroke as judged by the investigator, and
provided written informed consent.15 Risk factors for
stroke were not prespecified nor limited to the compo-
nents of existing risk stratification schemes, such as
CHA2DS2-VASc. Patients with a transient reversible cause
of AF and those for whom follow-up was not possible
were excluded.
To study the evolution of antithrombotic management
at diagnosis of AF, consecutive patients were enrolled
prospectively into 5 sequential cohorts (representing
the 5.5 years of enrolment) from March 2010 to July
2016; each cohort included approximately 10,000
participants. Supplementary Figure S1 shows the in-
creasing NOAC use in AC recipients by date of enrolment
in all countries from 2013 to 2016. In this report, the
analysis focuses on the latter years of recruitment after at
least 1 NOAC was licensed in all 35 countries in the
GARFIELD-AF registry, that is, cohorts (C) C3 (2013-
2014), C4 (2014-2015), and C5 (2015-2016), when
NOAC prescribing rose from a median of 33.8% to
62.6% of patients on AC therapy.
Cross-sectional data at baseline including treatment
patterns (NOAC relative to VKA) for all patients on an AC
with or without antiplatelet (AP) therapy are reported.
The data were extracted from the study database on
October 2017. This article has been written according to
the standards outlined by the Strengthening the Report-
ing of Observational Studies in Epidemiology statement.
The registry is being conducted in accordance with the
principles of the Declaration of Helsinki, local regulatory
requirements, and the International Conference on
Harmonization–Good Pharmacoepidemiological and
Clinical Practice guidelines. GARFIELD-AF data are
captured using an electronic case report form designed
by Dendrite Clinical Systems Ltd (Henley-on-Thames,
UK). Data management and quality assurance processes
have been described previously.16
Statistical analysis
Patients who were not prescribed AC at enrolment
were excluded from these analyses. Patient characteris-
tics and medical history were described according to the
use of AC therapy, that is, NOAC ± AP or VKA ± AP
therapy, respectively. Complete case analysis was used
for the description of medication use. Data gathered on
patients characteristics included demographics (gender,
age, race), clinical findings and history (type of AF,
alcohol use, smoking status, body mass index [BMI],
diabetes, systolic and diastolic blood pressure [BP], heart
rate, history of stroke and/or transient ischemic attack,
history of systemic embolism, history of bleed, hyperten-
sion, cirrhosis, history of coronary artery bypass graft
[CABG], heart failure, kidney disease, history of acute
coronary syndrome [ACS], vascular disease, dementia, or
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hypo- or hyperthyroidism), and AP therapy. Age, BP, and
heart rate were assessed as continuous variables.
Logistic least absolute shrinkage and selection operator
regression determined predictors of NOAC and VKA use
based on data collected at enrolment. Four models were
generated, each adding additional information, to estab-
lish the association of treatment decision with patient
(clinical and demographic) characteristics (model 1),
then the addition of cohort (ie, year of enrolment) to
patient characteristics (model 2), the addition of site of
enrolment to the other 2 sets of information (model 3), and
finally the addition of country to all covariates in models 1-3
combined (model 4). The linearity assumption was evaluat-
ed for each continuousmeasure by applying restricted cubic
splines. The association between date of enrolment and
NOAC use versus VKA use was estimated using a restricted
cubic spline. The predicted values and 95% CIs from the
unadjusted models displayed the relationship of increasing
NOAC use with time. Data analysis was performed with SAS
version 9.4 (SAS Institute Inc, Cary, NC, USA).
This work was supported by an unrestricted research
grant from Bayer AG (Berlin, Germany) to the Thrombosis
Research Institute (London, UK), which sponsors the
GARFIELD-AF registry. The funding source had no
involvement in the data collection, data analysis, or data
interpretation. The authors are solely responsible for the
design and conduct of this study, all study analyses, the
drafting and editing of the paper, and its final contents.
Results
Global prescribing trends
Of the 34,865 patients enrolled into GARFIELD-AF
between April 2013 and August 2016, 24,137 patients
who received AC ± AP therapy (NOAC [51.4%] or VKA
[48.6%]) as their first treatment after diagnosis of AF were
included in this analysis, and 10,717 patients on AP therapy
only or no stroke prevention treatment were excluded.
A description of the prescribing across all 35 countries
is depicted in Figure 1 (and Supplementary Figure S2).
The figure shows the marked variability in NOAC
prescribing between countries, ranging from 6.1% (in
Thailand) to 87.5% (in Switzerland) of all AC-treated
patients (Figure 1). When evaluating prescribing trends
over time between April 2013 and August 2016, NOAC
use increased year on year in most but not all countries so
that by the last quarter of enrolment, for example, NOACs
represented 100.0% of AC prescribing in Austrian
patients but only 9.4% of AC prescribing in Hungary
(see Supplementary Figure S3).
Characteristics of the study population
The baseline characteristics of patients on AC ± AP
therapy are summarized in Table I as well as the care
setting (Supplementary Table SI). The median age of
patients at the time of initiating AC for stroke prophylaxis
was 72.0 years for NOACs and 71.0 years for VKAs. More
Figure 1
National variations in NOAC use in AC recipients at the time of diagnosis of AF (based on data collected between 2013 and 2016 for GARFIELD-
AF cohorts 3 to 5).
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Table I. Baseline characteristics of patients stratified by first AC treatment following diagnosis of AF
Variable at enrolment NOAC
(n = 12,395)
VKA
(n = 11,742)
Gender, n (row %)
Male 6951 (52.2) 6360 (47.8)
Female 5444 (50.3) 5382 (49.7)
Age at AF diagnosis (y), median (IQR) 72.0 (64.0-79.0) 71.0 (64.0-78.0)
Age group, n (row %)
b75 y 7451 (50.6) 7284 (49.4)
≥75 y 4944 (52.6) 4458 (47.4)
Ethnicity, n (row %)
Caucasian 7867 (51.0) 7553 (49.0)
Hispanic/Latino 530 (35.8) 951 (64.2)
Asian (not Chinese) 3205 (58.4) 2288 (41.7)
Chinese 176 (26.8) 481 (73.2)
Afro-Caribbean/mixed/other 300 (54.6) 250 (45.4)
Alcohol consumption, n (row %)
Abstinent 5332 (48.8) 5605 (51.3)
Light 3642 (52.8) 3259 (47.2)
Moderate 1159 (58.0) 839 (42.0)
Heavy 207 (48.9) 216 (51.1)
BMI, median (IQR) 27.0 (24.0-31.0) 27.0 (24.0-31.0)
Pulse (beat/min), median (IQR) 85.0 (70.0-107.0) 85.0 (72.0-104.0)
Systolic blood pressure (mm Hg), median (IQR) 132.0 (120.0-145.0) 131.0 (120.0-145.0)
Diastolic blood pressure (mm Hg), median (IQR) 80.0 (70.0-88.0) 80.0 (70.0-90.0)
Type of AF, n (row %)
New onset (unclassified) 4814 (47.7) 5272 (52.3)
Paroxysmal 4057 (61.2) 2568 (38.8)
Persistent 2078 (51.2) 1980 (48.8)
Permanent 1446 (42.9) 1922 (57.1)
Heart failure, n (row %)
No 10,073 (51.9) 9356 (48.1)
Yes 2321 (49.3) 2386 (50.7)
Acute coronary syndrome, n (row %)
No 11,280 (51.9) 10,477 (48.1)
Yes 1056 (47.0) 1191 (53.0)
Vascular disease, n (row %)
No 10,711 (52.0) 9880 (48.0)
Yes 1634 (47.4) 1810 (52.6)
History of stroke/TIA, n (row %)
No 11,024 (51.6) 10,328 (48.4)
Yes 1370 (49.2) 1414 (50.8)
Hypertension, n (row %)
No 2924 (54.6) 2428 (45.4)
Yes 9439 (50.5) 9266 (49.5)
Diabetes, n (row %)
No 9730 (52.7) 8746 (47.3)
Yes 2664 (47.1) 2996 (52.9)
Chronic kidney disease, n (row %)
None or mild (grades I and II) 10,763 (52.8) 9632 (47.2)
Moderate to severe (grades III to V) 1202 (45.8) 1421 (54.2)
AP therapy, n (row %)
No 10,357 (53.4) 9034 (46.6)
Yes 2038 (42.9) 2708 (57.1)
CHA2DS2-VASc score, median (IQR) 3.0 (2.0-4.0) 3.0 (2.0-4.0)
CHA2DS2-VASc categories, n (row %)
≤1 1669 (57.4) 1237 (42.6)
2-3 5479 (51.3) 5200 (48.7)
N3 4970 (49.9) 4984 (50.1)
HAS-BLED score,⁎ median (IQR) 1.0 (1.0-2.0) 1.0 (1.0-2.0)
TIA, transient ischemic attack.
⁎ The risk factor “Labile INRs” is not included in the HAS-BLED score because it is not collected at baseline. As a result, the maximum HAS-BLED score at baseline is 8 points (not 9).
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Figure 2
a
b
Relative significance (measures as Wald χ2 statistic minus the number of degrees of freedom) associated with NOAC versus VKA prescribing
based on 2a. Model 4 including country, site characteristics, cohort, and patients' baseline characteristics. 2b. All models including patient
characteristics are presented in descending order of significance.
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patients of Asian ethnicity (not Chinese) were prescribed
NOACs than VKAs. VKAs seemed to be favored for the
treatment of Hispanic/Latino and Chinese populations.
Patients with new-onset (unclassified) AF and permanent
AF were preferentially prescribed VKAs, whereas NOACs
appeared to be more frequently prescribed in patients
with paroxysmal AF. Fewer patients on NOACs than
VKAs received concomitant antiplatelet therapy (16.4%
vs 23.1%). Patients in both groups had a median
CHA2DS2-VASc score of 3, although a slightly higher
proportion of patients on VKA had diabetes, and vascular
disease. Conversely, a greater proportion of patients on
NOACs (13.8%) than on VKAs (10.8%) had a low stroke
risk (CHA2DS2-VASc ≤1).
Relationship between baseline variables and choice of
anticoagulant
A complete list of variables associated with prescribing
choice selected in all 4 least absolute shrinkage and
selection operator regression models are described (see
Supplementary Table SII). Overall, the final model
(including all baseline variables) predicted AC prescrib-
ing with the greatest accuracy (C statistic of 0.81). When
evaluating all 4 sets of factors in this model, the country in
which the patient was enrolled far outweighed all other
factors in terms of statistical significance (Figure 2, a).
When country was not included in the model, the year of
enrolment was the most significant factor followed by the
setting in which patients were enrolled (Supplementary
Table SII). Overall, patients' (demographic and clinical)
characteristics were statistically the least significant
factors in determining choice of AC.
Figure 2, b shows the relative importance of the patient
characteristics in all 4 models. Type of AF, concomitant
antiplatelet therapy, and kidney disease were strongly
associated with the choice of AC therapy in each model.
Similarly, alcohol use, diabetes, and heart rate also remained
significantly associated with AC choice in each model.
Ethnicity, which is highly correlated with geographic
location, was one of the strongest predictors of the choice
of AC in all models, except the final model which included
country. The age of patients at the time of diagnosis of AF
also became a nonsignificant predictor of AC choice in the
presence of country, yet vascular disease and heart failure
were significant in the presence of country.
Factors determining the choice of NOAC or VKA
Results obtained from the final model suggest that
patients enrolled in the emergency care setting or in the
outpatient setting (ie, at an office or anticoagulation
clinic) were more likely to receive a NOAC than a VKA
prescription as their first treatment for stroke prevention
than patients enrolled in the hospital (OR 1.16 [95% CI:
1.04-1.30], OR: 1.15 [95% CI: 1.05-1.25], respectively).
Overall, neurologists were most likely to prescribe
NOACs. Compared with cardiologists, primary care
physicians and internists were less likely to initiate
treatment with NOACs (OR: 0.55 [95% CI: 0.50-0.62],
OR: 0.89 [95% CI: 0.81-0.97], respectively) (Supplemen-
tary Figure S4).
Model 4 found that patient characteristics which
predicted NOAC prescribing included year of enrolment
(designated by cohort), ACS, paroxysmal AF (relative to
new onset AF), increasing age (as assessed over 5-year
increments) in patients up to 75 years and beyond
75 years, and normotensive patients (defined by a systolic
blood pressure up to 120 mm Hg) (Figure 3 and
Supplementary Table SIII). Conversely, factors which
predicted a VKA prescribing included moderate to severe
kidney disease, vascular disease, heart failure, diabetes,
concomitant antiplatelet therapy, permanent AF, and
Chinese ethnicity (Figure 3).
Discussion
There is still much to learn about how NOACs are being
used in clinical practice and their impact on short- and
long-term outcomes in patients with AF. A principal aim
of the GARFIELD-AF registry was to document changes in
treatment practice at a national and global level for patients
with newly diagnosed AF during an era when NOACs are
becoming more widely adopted.14,15 Although the indica-
tions and eligibility of patients for NOACs and VKAs are
well codified by prescribing information, clinical guide-
lines, expert opinion, and a wealth of published data,7,17-20
the large global data set from GARFIELD-AF provides an
opportunity to evaluate the key drivers of NOAC and VKA
prescribing across a range of care settings in everyday
practice.
Unsurprisingly, the registry recorded enormous variabil-
ity in prescribing practice reflecting the heterogeneity in
the organization of health care across the globe.5 NOACs
weremost commonly used as an initial treatment for stroke
prevention in countries where there is a high per capita
spend on health via Medicare (such as in the United States)
or universal health care coverage. Whereas in participating
centers in other countries with more restricted public
funding (including Hungary, Czech Republic, Ukraine,
Spain, Argentina, Brazil, Chile, Egypt, South Africa, India,
China, and Thailand), VKA was most commonly used.
For participating centers in some countries, early and
broad access to NOACs meant that NOACs had already
become the preferred option by the start of the analysis
(ie, April 2013). These countries included Japan, the
United States, Belgium, France, Germany, Austria, Swit-
zerland, and Norway (Supplementary Figure S3). How-
ever, for countries such as the United Kingdom, state-
funded reimbursement for NHS patients was only made
available in 2014 after the National Institute for Health
and Care Excellence guideline was updated.21 In Canada,
an initial disconnect between recommended NOAC
therapy and insurance coverage resulted in a delay in
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patient access to NOACs.22 Consistent with the published
observations from national registries,23-27 GARFIELD-AF
recorded an initially slow but nevertheless steady rise in
NOAC prescribing between 2013 and 2016 at participat-
ing centers in many countries including Australia,
Netherlands, Denmark, Sweden, Finland, Russia, Poland,
Italy, Turkey, United Arab Emirates, Mexico, Singapore,
and Korea (Supplementary Figure S3). Key drivers for this
change included new guidelines from the European
Society of Cardiology,4 European Heart Rhythm Associ-
ation,28 and American College of Cardiology/American
Heart Association29 as well as national policy documents
(such as the Canadian guidelines and National Institute
for Health and Care Excellence) based on reappraisal of
the evidence on NOACs.
At a national level, it was observed that physician-
specific prescribing habits and the care setting came to
the fore in determining the choice of AC. Consistent with
Figure 3
Adjusted OR
0.25 0.5 0.75 1.0 1.5 2.0 3.0 4.0 
Female (ref. Male)
Age (5-year increments)
Up to 75 years
75 years or older
Ethnicity (ref. Caucasian)
Hispanic/Latino
Asian (not Chinese)
Chinese
Afro-Caribbean/Mixed/Other
Alcohol consumption (ref. Abstinent)
Light
Moderate
Heavy
BMI (1 kg/m
2
 increments)
Pulse (5 bpm increments)
Up to 80 bpm
80 bpm or more
Systolic blood pressure (5 mmHg increments)
Up to 120 mmHg
120 mmHg or more
Diastolic blood pressure (5 mmHg increments)
Type of AF (ref. New onset [unclassified])
Permanent
Persistent
Paroxysmal
Congestive heart failure
Acute coronary syndromes
Hypertension
Vascular disease
Diabetes
Moderate to severe CKD
Antiplatelet therapy
Cohort (ref. Cohort 3)
Cohort 4
Cohort 5
Adjusted OR (95% CI)
0.98 (0.92-1.05)
1.02 (1.00-1.04)
1.02 (0.97-1.06)
0.78 (0.62-1.00)
0.75 (0.55-1.02)
0.46 (0.22-0.93)
0.86 (0.70-1.06)
1.08 (0.98-1.18)
1.20 (1.06-1.35)
0.91 (0.73-1.14)
1.00 (0.99-1.01)
0.96 (0.94-0.98)
1.02 (1.01-1.03)
1.04 (1.01-1.08)
1.00 (0.98-1.01)
1.00 (0.98-1.02)
0.80 (0.73-0.88)
0.94 (0.86-1.04)
1.24 (1.14-1.34)
0.81 (0.75-0.88)
1.20 (1.02-1.42)
0.96 (0.89-1.04)
0.77 (0.67-0.89)
0.88 (0.82-0.95)
0.72 (0.65-0.79)
0.73 (0.67-0.80)
1.76 (1.63-1.90)
3.30 (3.05-3.57)
Favors VKA prescription Favors NOAC prescription
Adjusted ORs for NOAC prescription among OAC recipients by baseline characteristics and cohort of enrolment.
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other published studies,24,30,31 both cardiologists and
neurologists (rather internists) were clearly early adopters
of NOACs for stroke prevention,32 acting as “anticoagulant
champions” for physicians less familiar with these new
therapies.33 Equally, the lack of uptake of NOACs in some
fields of medicine and clinical settings may have been the
consequence of limited or restricted funding, or prescrib-
ing regulations. For example, the prescribing choices of
primary care physicians and general physicians who work
in smaller community hospitals and practices serving
poorer communities32 may be restricted because of
financial constraints on funding and insurance limitations
or because of the imposed need to restrict prescription to
the best informed health care professionals.
Overall, prescribing of AC therapy for stroke prevention in
AF patients appears to be more common in the outpatient
setting.34 The GARFIELD-AF registry and a number of other
studies33 have found that patients who are managed in the
outpatient setting are more likely to receive NOAC therapy
than patients treated in emergency care or in the hospital
setting. The prescribing policy of many hospitals and clinics
with established monitoring services for VKA may have
restricted NOAC prescribing until after a trial period with a
VKA. In the Netherlands, for example, a nationwide
network of anticoagulant clinics monitors the vast majority
of patients on anticoagulants, and so the availability of these
ancillary services has meant that the uptake of NOACs has
been relatively slow comparedwith neighboring Belgium.33
The variation in the choice of AC also reflects the
differing values and preferences among physicians and
patients.35-37 Many physicians and patients express a
preference for NOACs due to reduced potential for food
and drug interactions and reduced need for monitoring.38
However, other studies have also described the preferen-
tial use of VKAs by physicians in the outpatient setting38
because of the availability of portable home testing, which
allows patients to self-manage their treatment and provides
physicians with information to assess patients' compliance
to treatment.39
Consistent with observations from the national Danish
registry,27 GARFIELD-AF shows that NOACs seemed to be
favored for the management of patients with a low stroke
risk (CHA2DS2-VASc 0 or 1) as well as the elderly and
patients with ACS. VKAs were more often prescribed in
patients with CKD, diabetes, heart failure, and permanent
AF.40 It is well recognized that VKAs are the treatment of
choice41,42 in cases of severe renal failure and severe
cardiac structural alterations.
Ethnicity was found to be significant in the model of
patient characteristics but became borderline when
country was added to the model. Not surprisingly, there
is a strong correlation between these 2 factors. It is
interesting to note the striking difference in NOACs used
across the Asian countries. Thus, we have separated the
Chinese Asian ethnicity. Because some ethnicity
remained in the presence of country, it is possible that
the remaining differences are between health care
systems. In the case of Asian countries, it may be that
the differences noted are driven by the lack of
reimbursement of NOACs in China.
It is likely that concerns may exist regarding the
increased risk of major bleeding complicating VKA
therapy in the elderly43 and especially those with a
high risk of fall or dementia. Our analyses also provide
evidence about ongoing concerns regarding the prescrip-
tion of NOACs for patients with renal dysfunction.
However, it may only be a question of time before the
favorable findings from recent randomized clinical trials
(RCTs) with NOACs are influencing clinical practice.
Subgroup analyses from RCTs with rivaroxaban or
apixaban have shown the benefits of these NOACs
when compared to warfarin.44,45 Data from phase III
trials also suggest that the preservation of renal function
was significantly better with rivaroxaban than warfarin.46
These findings were corroborated by Yao et al (2017) in a
US retrospective cohort analysis of the Opted-Labs Data
Warehouse database,47 which compared the impact of
NOACs (apixaban, dabigatran, and rivaroxaban) and
warfarin on renal outcomes. The authors found that the
use of NOACs was associated with reduced risks of
progressive renal impairment, manifest as ≥30% decline
in eGFR, doubling of serum creatinine, and acute kidney
disease developing over time.
Although use of NOACs was more common than VKAs
in patients with ACS, a separate unpublished GARFIELD-
AF analysis found that antiplatelet therapy (either alone,
ie, without OAC, or in combination with OAC) is used in
approximately two-thirds of patients in this setting. The
value of NOACs in patients with vascular disease, recently
described in published studies,48 has yet to be realized in
everyday clinical practice.
GARFIELD-AF showed that VKAs are more likely to be
used in combination with AP therapy than NOACs,
although the evidence from many studies suggests that
stopping AP therapy would almost certainly diminish the
bleeding risk without increasing CVD risk.49 In a separate
GARFIELD-AF analysis, an overall decline over time was
seen in the nonindicated use of AP therapy (both as a
monotherapy and in combination with AC).50
Strengths and limitations
This study describes real-world clinical practices in AC
prescribing for a well-defined cohort of patients with
newly diagnosed nonvalvular AF and at least 1 risk factor
for stroke. However, in contrast to RCTs, AF patients with
many concomitant diseases were not excluded from this
noninterventional registry. This observational study was
sufficiently large to identify hospital and other care
settings which were representative in each country. With
patients recruited within 6 weeks of diagnosis of AF, the
registry provided a record of almost all patients treated in
each participating center with nonvalvular AF, that is,
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including some high-risk patients who died shortly after
diagnosis. GARFIELD-AF mitigated some of the limitations
inherent to observational studies through the standardi-
zation of clinical definitions and the rigorous audit (using
both remote and onsite monitoring) to ensure the
completeness and accuracy of the data collected. This is a
unique feature because GARFIELD-AF is a prospective
global disease registry and regional differences and
country-related variations of drug prescribing patterns
had been anticipated. Other studies addressing the
predictors of NOAC use where smaller, retrospective,
limited to selected patient populations, limited to single
countries or regions within a country, or monocenter
observations. A small study of Guerriero et al was limited to
967 patients in South Italy and assessed the predictive role
of age, gender, and number and type of co-treatments for
NOAC versus warfarin prescription in elderly patients. In
contrast to our findings, age was negatively associatedwith
NOAC initiation.51 A German claim data analysis of 16,804
elderly nursing home residents identified previous stroke,
bleeding events, and a recent hospitalization as predictors
for NOAC prescription instead of VKA.52 An analysis of
health insurance data of the Canadian Province of Quebec
showed that initiation with NOACs was less likely for
patients≥80 years old (OR 0.55, 95% CI 0.41-0.73) or with
CHA2DS2-VASc≥2 (OR 0.49, 95% CI 0.42-0.57).53 Another
group of authors addressed the effect of NOACs on
prescribing practices for AF in older adults by using the
database of their hospital, the academic medical center in
St Louis, MO, USA. Consistent with our results, they
observed an increase of NOAC use over, time but in
contrast to GARFIELD-AF, the rate of NOAC uptake was
attenuated by increasing age.54 The group of Urbaniak et al
used the Norwegian Prescription Database to analyze the
prescription patterns ofNOACs inNorway, and they report
that AF patients b70 years old had higher odds of NOAC
prescribing (OR 1.19-1.29, depending on age category) in
contrast to patients N74 years old (OR 0.51-0.77).26 The
aim of a Canadian study was to identify factors that predict
selection of a NOAC by resident physicians when faced
with patients with nonvalvular AF. The most consistent
predictor for prescribing a NOAC in all clinical scenarios
was self-reported comfort level.55 The ORBIT-AF II study
group also aimed to describe the factors associated with
selection of NOACs versus warfarin in patients with new-
onset AF. Their findings related to patient characteristics
are not too different from our observations in GARFIELD-
AF; however, ORBIT-AF II is limited to patients in United
States, whereas GARFIELD-AF is a global registry. The
impact of the health insurance status on the prescription
pattern could be analyzed in more detail in ORBIT-AF II.
This would have been too confounded in GARFIELD-AF
due to reimbursement differences in each country.56 None
of these publications addressed the role of different
countries as a predictor of treatment, which was the
most important factor in GARFIELD-AF with 35 contribut-
ing countries. We also show the uptake of NOAC use by
country, and we provide information on the impact of the
care setting specialty (cardiology, geriatrics, internal
medicine, neurology, primary care/general practice) and
the location of enrolment (anticoagulation clinic/thrombo-
sis center, emergency room, hospital, office).
This study, however, also has limitations. Firstly,
although patients were recruited consecutively, informed
consent was required, thereby introducing a level of bias
in the patient selection. Secondly, comorbidities (such as
cancer) and other factors, which would have likely
impacted on the choice of treatment, were not compre-
hensively reported. Thirdly, the impact of drug costs and
levels of reimbursement could not be quantified accu-
rately, but this is likely to be a main driver limiting access
to NOACs for a broad cross section of eligible patients.
Finally, there are likely to be other factors relating to
patient preferences, which were not reported.
Conclusions
GARFIELD-AF shows that prescribing of NOACs has
increased substantially during the course of the study.
With this change, an overall increase in AC prescribing
was also observed. GARFIELD-AF highlighted marked
differences in the stroke prevention strategies which are
adopted around the world. This heterogeneity may be
explained by substantial differences in health systems
across countries as well as differences between specialty
practice and differences in patient characteristics. In the
years shortly after approval of NOACs for stroke
prevention, prescribing of NOACs seems to have been
favored in the lower-risk groups, such as patients with
paroxysmal AF and/or a low stroke risk (CHA2DS2-VASc 0
or 1), but also in the elderly and patients with ACS,
whereas physicians now appear to prefer prescribing
VKAs in patients with permanent AF, moderate to severe
kidney disease, or heart failure and those with vascular
disease and diabetes mellitus. It is likely that further
changes in AC prescribing may evolve as physicians'
experience with NOACs mature for stroke prevention as
well as other indications and as initial concerns over the
safety and reversibility abate. However, the countries and
the cohorts reflecting the time of enrolment were the
strongest predictors of NOAC versus VKA prescription
for stroke prevention in patients with newly diagnosed
atrial fibrillation.
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